The ability of endothelial cells to activate helper T (Th) cells by antigen presentation was studied using the murine endothelial cell line SVEC4-10 and antigen-specific murine T cell clones. SEVEC4-10 cells constitutively express vascular cell adhesion molecule 1 but not intercellular adhesion molecule 1. Interferon 7 (IFN-7) treatment of these cells induced class II major histocompatibility complex (MHC) expression and antigen-presenting capabilities, but did not alter surface integrin expression. IFN-7-treated SVEC4-10 cells were competent at mediating antigen-dependent cytokine production and proliferation ofa Th2 done. In contrast, endothelial antigen presentation to Thl cells did not stimulate T cell proliferation. The addition of MHC mismatched spleen cells as a source ofcostimulatory molecules resulted in the ability of the endothelial cells to stimulate Thl cell proliferation in an antigen-spedfic manner. The failure of the endothelial cell line alone to support Thl cell proliferation correlated with the failure to stimulate interleukin 2 (IL-2) gene expression. T cell exposure to the endothelial cells plus antigen resulted in upregnlation of IL-2 receptors and an enhanced response to subsequent antigen presentation by splenic antigenpresenting cells. Despite the lack of functional costimulators for IL-2 expression, antigen presentation by the endothelial cell line did not induce Thl cell anergy, indicating that costimulator deficiency for IL-2 expression is not obligatorily linked to anergy induction. Thus, endothelial cells are capable of presenting antigens to helper T lymphocytes, but stimulate only partial T cell responses. These partial responses may serve to selectively stimulate transmigration of antigen-specific T cells and may enhance functional responses upon subsequent, extravascular antigen exposure.
T he initiation and regulation of immune responses to foreign antigens is dependent on antigen presentation to CD4 + helper T lymphocytes. An effective APC must be able to internalize and process exogenous protein antigens and express peptide fragments of these antigens in association with class II MHC molecules at the cell surface to activate antigen-specific T cells. In addition, APCs express costimulatory molecules that bind to signal generating membrane ligands on the T cells. The antigen-presenting functions of several cell types have been well described, including macrophages (1), B lymphocytes (2, 3) , and dendritic cells (4) . Endothelial cells are a potentially significant APC population in vivo because of their cumulatively large surface area and their anatomic location between circulating T cells and extravascular sites of antigen exposure. The ability of vascular endothelial cells to present exogenous protein antigen to class II-restricted helper T cells in vitro has been described several times (5) (6) (7) (8) (9) , but this function has been incompletely characterized in light of recent insights into the role of adhesion molecules and costimulatory pathways in T cell activation. In part, APC function of any cell type may be determined by the regulation of class II MHC expression. Class II MHC molecule expression can be induced on cultured human (10, 11) and mouse (12, 13) endothelial cells by IFN-% In vivo, peripheral human venular endothelial cells express class II MHC constitutively (11, 14, 15) and murine endothelial cells express class II MHC at sites of active immune-mediated inflammation, such as allograft rejection (16) and autoimmune encephalitis (17) .
The expression of costimulatory activities by endothelial cells has only been preliminarily characterized. One endothelial costimulatory activity for T cell activation has been defined on the basis of the ability of human umbilical vein endothelial cells to augment IL-2 secretion by PHA-stimulated peripheral blood T cells (18, 19) . This activity is dependent on CD2-LFA-3 interactions. The presence of costimulatory activity on endothelial cells has been inferred from experiments demonstrating the ability of pure endothelial cultures to stimulate proliferative responses of different T cell populations, including naive alloreactive T cells (20) and memory T cells specific for exogenous protein antigens (21) . The presence or absence of endothelial costimulators for distinct subsets of differentiated helper T cells has not been examined.
The presence or absence of costimulators on APCs may profoundly influence the outcome of T cell antigen recognition. With costimulators present, antigen presentation results in IL-2 gene expression, T cell proliferation, and the generation of T cell progeny capable of responding to subsequent antigen exposure. In contrast, several experimental models have suggested that antigen presentation in the absence of costimulators causes suboptimal or no IL-2 gene expression (22, 23) . Furthermore, costimulator-deficient APC may induce a long-lived anergic state in which the T cell cannot transcribe its IL-2 genes in response to subsequent antigen recognition (22) (23) (24) (25) (26) (27) (28) . This phenomenon of donal anergy has largely been studied using murine Thl clones together with APCs that are chemically fixed to destroy mostly uncharacterized costimulatory activities (27) . There is evidence that some unfixed cell types, such as keratinocytes (29) and renal tubular epithelial cells (30) may induce anergy, presumably because of the lack of expression of costimulators. Furthermore, T cell anergy has been induced by T cell receptor stimulation in the complete absence of accessory cell costimulators using peptide bound to MHC molecules on planar membranes (31), or immobilized antireceptor antibodies (32) .
In this paper, we describe the antigen-presenting functions of a well differentiated murine endothelial cell line, SVEC4-10 (13). Our findings indicate that these endothelial cells have the capacity to stimulate proliferation of some helper T cells but not others. Furthermore, we show that the inability to stimulate some T cells is due to a lack of costimulators, which can be supplemented by the addition of nonantigen-presenting allogeneic spleen cells. Importantly, these viable, costimulatordeficient endothelial cells do not induce anergy in the A.E7 T cell clone that has been used as a prototype for anergy induction by chemically fixed APCs (26) (27) (28) (33) (34) (35) (36) (37) . The findings are discussed in the context of a hypothetical role of endothelial antigen presentation to circulating T cells.
Materials and Methods
Mice. BALB/cJ and AKR mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Cell Lines. The endothelial cell line SV4EC-10 (13) derived from a C3H/HeJ mouse lymph node was obtained from Dr. Michael Edinin (Johns Hopkins University, Baltimore, MD), and grown in DME with 10% FCS. Some SVEC4-10 cultures were treated with 100 U/rrd recombinant murine IFNw (Genzyme Corp., Cambridge, MA) for 6 d before use in functional assays to induce class II MHC expression. The mouse CD4 + helper T cell clones used in these studies included: A.E7, specific for pigeon cytochrome C + I-E k, a gift of Dr. Ronald Schwartz (National Institutes of Health, Bethesda, ME)); 100.9, specific for rabbit 3, globulin + I-A k, a gift of Dr. Abul Abbas (Brigham and Women's Hospital, Boston, MA); and D10.G4, spedtic for conalbumin + I-A k, obtained from the American Type Culture Collection (Rockvilh, MD). The clones were maintained in ILPMI 1640 supplemented with 10% heatinactivated FCS (Hydone Laboratories, Logan, UT), penicillin (100 U/ml), streptomycin (100/~g/ml), 2 mM t-glutamine, nonessential amino acids (0.1 raM), sodium pyruvate (1 mM), and 5 x 10 -s M 2-mercaptoethanol. The clones were stimulated with 100 /zg/ml antigen plus 1,500 tad irradiated whole AKR spleen cells every 14 d. Recombinant routine I1:2 (10 U/ml) or supernatant from Con A-stimulated rat spleen cells (10% vol/vol) was added 4 d after stimulation. Pigeon cytochrome c (PCC),J conalbumin, and rabbit 3~ globulin were obtained from Sigma Chemical Co. (St. Louis, MO), The 81-104 peptide of the PCC molecule, recognized by the A.E7 done was a gift from Dr. Abul Abbas. Cloned T cells were harvested between 10 and 14 d after restimulation for experimental cultures, and viable T cells were isolated by centrifugation over FicoU-Diatrizoate (Organon Teknika, Durham, NC).
Mouse recombinant Ib2 was used as a culture supernatant from the x63-Ib2 cell line that constitutively expresses a transfected mufine II:2 gene, generously provided by Dr. Fritz Melchers (Basel Institute for Immunology, Switzerland) (38) . Bioactivity of recombinant II:2 preparations was determined using the HT-2 indicator line, as described below. One unit of I1:2 was defined as the amount required to produce half-maximal proliferation of the indicator cell line in a serial dilution assay.
Antigen Presentation Assays. Untreated or IFN-~,-treated SVEC4-10 cells were grown to confluence in gelatin-coated flat bottom 0.2-ml microtiter wells. The monolayers were treated with 50/zg/ml mitomycin C (Sigma Chemical Co.) for 90 min at 37~ washed, and 4 x 104 cloned T cells were added with or without antigen. T cell proliferation was assayed by labeling with [3H]TdR (Amersham Corp., Arlington Heights, IL) (1/zCi/well) for the final 6 h of a 3-d culture. Incorporated radioactivity was measured in a Betaplate scintillation counter (LKB-Pharmacia, Gaithersburg, MD). To measure secretion of I1:2, 50-/~1 aliquots of supernatant were collected from each microwel118 h after initiation of the culture and these were assayed for their ability to stimulate growth of the HT-2 indicator cells line (39) .
Assay for Anergy Induction. For the attempted induction of anergy, 5 x 10 s A.E7 T cells were cocultivated on IFN-y-treated SVEC4-10 monolayers in 2-ml wells for 24 h in the absence or presence of 10/~M PCC peptide fragment 81-104 or 100/~M intact PCC. The T cells were then removed from the monolayers and rested in tissue culture medium alone for either 48 h or 7 d. After rest, they were recultured in 0.2-ml wells at 2 x 104 viable cells per well and restimulated with irradiated AKR spleen cells plus PCC peptide or PCC as described above, or 10 U/ml recombinant murine I1:2 and T cell proliferation was measured at 48 h. As a positive control for anergy induction, primary cultures were also set up with 5 x 10 s A.E7 T cells and 2 x 106 AKR spleen cells that had been previously fixed with 50 mM ECDI as previously described (26) followed by rest and restimulation cultures identical to those described above.
lmmunofluorescence Assays. Immunofluorescent staining of SVEC4-10 cells was performed on single-cell suspensions prepared from subconfluent monolayers by EDTA treatment. The cells were incubated with primary unlabeled rat anti-mouse mAbs of the appropriate specificities at 4~ for 30 min, washed in ice-cold serumfree tissue culture medium, and incubated for an additional 30 min at 4~ with FI~IXZ-hbeled goat anti-rat Ig (Southern Biotechnology Associates, Birmingham, AL). The cells were then washed in icecold PBS, fixed in 1% paraformaldehyde, and analyzed by flow cytometry on a FACScan | instrument (Becton Dickinson & Co., Mountain View, CA). T lymphocytes that were cocultured on 1 Abbreviations used in this paper: ECDI, 1-ethyl-3-(3-dimethyhminopropyl) carbodiimide-HCL; PCC, pigeon cytochrome c. SVEC4-10 monolayers for 24 h were harvested by gentle pipetting and stained in the same manner.
Monoclonal Antibodies. The primary rat anti-mouse antibodies used for immunofluorescence staining included M5114 spedfic for class II MHC I-A molecules (40), YNI.1 specific for intercellular adhesion molecule I (ICAM-1) (41), and 7D4 specific for the II,2 receptor c~ chain (42) , all were obtained from the American Type Culture Collection. In addition, MK-2 specific for vascular cell adhesion molecule 1 (VCAM-1) (41) was obtained from Dr. Paul Kincede (University of Oklahoma, Tulsa, OK). Purified anti-mouse CD28 (Pharmingen, San Diego, CA) was used in some antigen presentation assays.
RNA Isolation and Reverse Transcription PCR Analysis of lL.2 Gene Expression.
A.E7 cells were cocultured on monolayers of IFN-ytreated SVEC4-10 cells in 2 ml polystyrene wells at 106 T cells per well in the absence or presence of 5 x 106 BALB/c spleen cells plus or minus 100/~g/ml PCC. Viable T cells were harvested from the monolayers after 6 h, total cellular KNA was isolated using RNAzol TM (Biotecx Laboratories, Inc., Houston, TX), and reverse transcriptase (RT)-mediated synthesis of cDNA was performed with an oligo(dT) primer. The cDNA samples were precipitated using 0.2 M ammonium acetate (pH 4.5) and 2 vol absolute ethanol. The cDNA samples were then resuspended in 50 #1 of water, and 2.5/zl was used for PCR amplification with mouse IL-2 (43) and B-actin-specific primers. Following amplification, the PCK products were analyzed by ethidium bromide staining in agarose gels using standard techniques (44) .
Results
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activity to CD4 + T cells depends on class II MHC expression by the APC. SVEC4-10 cells do not constitutively express class II MHC, but they can be induced to do so by treatment with IFN-'y ( Fig. 1) , as has been reported (13) . Expression by SVEC4-10 cells of ligands for lymphocyte integrins was previously uncharacterized. The SVEC4-10 line constitutively expresses VCAM-1, but not ICAM-1 (Fig. 1) , and these phenotypic features were not altered by IFN-'r treatment (not shown).
SVEC4-10 Endothelial Cell Antigen Presentation to T Cell
Clones. The capacity of the SVEC4-10 line to support antigen-specific stimulation of murine helper T cell clones was tested using a Th2-type murine helper T cell clone, D10.G4, and two Thl type clones, A.E7 and AR100. Antigen recognition by all three clones is restricted to class II MHC alleles of the k haplotype; the SV4EC-10 cell line was derived from an H-2 k mouse (C3H/HeJ). IFN-7-treated SV4EC-10 cells were effective APCs for the Th2-type T cell clone D10.G4, as assessed by antigen-specific induction of T cell proliferation. Endothelial cells not treated with IFN-3/ did not present antigen. In contrast, two H-2Lrestricted Thl-type T clones, A.E7 and AtL100, were not stimulated to proliferate by the IFN~-treated endothelial cell line (Fig. 2) .
Allogeneic Spleen Cells Complement SVEC4-1O Antigen Presentation to Induce A.E7 T Cell Proliferation. Antigen-induced
autocrine growth factor production by Thl clones is generally more dependent on accessory cell costimulator molecules than are Th2 clones. Therefore, the inability of SVEC4-10 cells to stimulate Thl cell proliferation, shown in Fig. 2 have been due to a lack of costimulators. Allogeneic spleen cells have been reported to provide costimulatory activity for A.E7 activation in experimental systems using chemically modified APCs (28) . To test whether allogeneic spleen cells would complement SVEC4-10 antigen presentation and allow tures of A.E7 cells and IFN-?-treated SVEC4-10 cells. Antigen-induced IL-2 bioactivity in supernatants of SVEC4-10 and A.E7 cocuhures was detected only when allogeneic spleen cells were added as costimulators (data not shown). Because A.E7 cells produce low levels of detectable supernatant IL-2 under any conditions, in our hands and others (45) costimulator-dependent IL-2 gene expression was analyzed by the more sensitive technique of RT PCR. As shown in Fig. 5 , antigen presentation by IFN-q,-treated SVEC4-10 did not induce the presence of IL-2 message in A.E7 cells unless allogeneic spleen cells were added. This was an antigen-specific effect, because no IL-2 message was observed in the absence of the PCC, regardless of the presence or absence of allogeneic spleen cells. The possibility that allogeneic spleen cells were acting through the CD28 costimulatory pathway was tested. No proliferation ofT cells or expression of IL-2 was seen in cocultures of A.E7 cells with SVEC4-10 cells plus antigen even when anti-mouse CD28 mAb was added at 25 or 100 #g/ml (data not shown).
Evidence for a Partial Activation Response of A.E7 Cells to SVEC4-10-Mediated Antigen Presentation.
Despite the observed lack of Thl cell proliferation, it remains possible that the endothelial cell line is capable of inducing antigen-specific functional changes in A.E7 cells. Even though autocrine growth of the T cells does not occur, A.E7 cells exposed to SVEC4-10 cells plus PCC do become more responsive to exogenously added IL-2 within 18 h (Fig. 6) . Furthermore, the expression of p55 subunit of the IL-2 receptor increases concomitantly with the observed increased functional response (Fig. 7) . These data indicate that the SVEC4-10 cells are effective in presenting antigen to, and inducing functional changes in, a Thl cell, but they are costimulator deficient as defined by their inability to induce autocrine growth factor-mediated T cell proliferation.
Failure of SVEC4-10 Cells to Induce Anergy in A.E7 Cells. The A.E7 clone has been extensively studied as a model for clonal anergy induction. The presentation of PCC peptide to A.E7 cells by APCs that have been rendered costimulator deficient by chemical fixation resuhs in an inability of the T cells to undergo autocrine IL-2-dependent proliferation upon subsequent presentation of antigen with normal APCs (28, 33, 35) . The lack of costimuhtors on SVEC4-10 cells demonstrated above suggested that these endothelial cells might induce anergy. To the contrary, A.E7 ceils cocultured with IFN-q,-treated SVEC4-10 cells plus PCC protein and then rested for 48 h before restimulation were not anergic (Fig. 8 A) . In fact, these T cells were more responsive to subsequent antigen presentation by spleen cells than if they had not previously been exposed to antigen. When A.E7 ceils were initially cultured with ECDI-treated spleen cells plus PCC peptide, their proliferative response to antigen presentation after 48 h rest was more then 90% inhibited compared to T cells initially cultured with ECDI-treated spleen cells without PCC peptide (data not shown). The lack of anergy induction by SVEC4-10 antigen presentation was observed in all of six separate experiments, including those in which the A.E7 cells were removed from maintenance cultures 7 or 14 d after the last antigen restimulation, and in experiments in which the A.E7 cells were grown in the absence or presence of exogenously added IL-2 before culture with the SVEC4-10 cells. Furthermore, anergy could not be demonstrated in A.E7 cells that were rested for a full 7 d after exposure to SVEC4-10 cells plus antigen to ensure that the T cell responsiveness to IL-2 was back to baseline (Fig.  8 B) . In the experiment shown, intact PCC protein was used because this is a more physiologically relevant form of antigen then high concentrations of preformed immunogenic peptide. Nonetheless, 10-#M PCC peptide 89-101 presented by SVEC4-10 cells also did not induce anergy in A.E7 cells. As a positive control for anergy induction, the proliferative responses of A.E7 cells to PCC and splenic APCs was measured 7 d after exposure to ECDI-treated spleen cells plus PCC peptide. This response was 75% inhibited (Fig. 8 B) compared to control cells cultured with ECDI-treated spleen cells but no peptide. The response to IL-2 at this 7 d time point was not altered by previous exposure to antigen, using either ECDI-treated spleen or SVEC4-10 cells.
Discussion
The present experiments were aimed at defining the functional interactions between endothelial cells and T lymphocytes using an in vitro mouse model system. In particular, the antigen presentation capabilities and costimulatory activities of a well-differentiated mouse endothelial cell line, SVEC4-10 were examined. The SVEC4-10 cell line was derived from a primary culture of mouse lymph node vascular endothelium by SV40 virus immortalization (13) . In addition to the previously reported markers of endothelial cell differentiation, such as acetylated-LDL receptor and factor VIII expression, we have shown it constitutively expresses VCAM-1 and not ICAM-1. VCAM-1 is a ligand for VLA-4 and is potentially important for traf~cking of antigen-specific T cells to sites of antigen challenge. In addition, VCAM-1 may deliver costimulatory signals to CD4 + T cells (46, 47) . The absence of ICAM-1 expression by this cell line should permit analysis of VCAM-l-dependent adhesive and stimulatory interactions in isolation from ICAM-1 effects. The ability of SVEC4-10 cells to support antigen-specific stimulation of the proliferation of the Th2 hdper T cell clone D10.G4 indicates that this endothelial call line can take up, process, and present a soluble protein antigen in a class II MHC-restricted manner. Although full activation of Th2 cells has less stringent requirements for costimulators, it is possible that IFN-'y treatment of the endothelial ceil line, required for class II MHC expression, also induced the expression of unidentified molecules required for Th2 cell proliferation. In contrast, SVEC4-10 cells were not capable of stimulating the proliferation of two different Thl T cell clones, including the well-described A.E7 done. This failure to induce proliferation correlated with the failure of the SVEC4-10 cells to induce the appearance of IL-2 mRNA. The data indicate that these endothelial cells lack costimulatory molecules required by A.E7 cells for antigen-induced activation of autocrine IL-2-mediated growth. The required costimulatory activity can be provided by third party allogeneic spleen cells. The ability of SVEC4-10 endothelial cells to stimulate proliferation of Th2 but not Thl ceils is consistent with a recent report that antigen presentation by brain microvessel endothelium also leads to Th2 but not Thl cell autocrine growth factor secretion and proliferation (48) .
The best-defined costimulatory system in T ceil activation is that involving B7-CD28 interactions (23, (49) (50) (51) (52) (53) (54) (55) . There are two reasons why it is unlikely that the absence or presence of B7 is playing a significant role in the T cell functional responses described here. First, there is evidence that B7 must be present on the APC for it to optimally costimulate T cell proliferation (56, 57) . In contrast, costimulatory activity for A.E7 proliferation that is missing on the SVEC4-10 ceils can be provided by nonantigen-presenting, third party allogeneic spleen ceils. Second, anti-CD28 antibody used under conditions reported to costimulate certain other T ceils in culture (58) did not have any effect on the ability of the SVEC4-10 cells to induce proliferation of the A.E7 cells. In addition to B7, both VCAM-1 and ICAM-1 have been implicated as costimulators ofT cell IL-2 production and proliferation (46, 47, (59) (60) (61) . ICAM-1 is not expressed on the SVEC4-10 ceils under the conditions used in the experiments reported here, and this is a possible reason for the incomplete T cell activation observed in response to the antigen presentation by the endothelial cell line. We believe that this is unlikely for three reasons. First, previous reports indicate that VCAM-1 and ICAM-1 are costimulators of resting T cells but not necessarily of T cells previously activated by antigens (47, (59) (60) (61) . In fact, it has been shown that IL-2 production by T cells previously activated by superantigen was not costimulated by either VCAM-1 or ICAM-1 (47) . In the studies reported here, the T ceil clones were activated by antigen within 14 d of the experimental culture. Second, when directly compared, VCAM-1 and ICAM-1 each independently costimulated TCRmediated proliferation of naive T cells equally well; that is, the presence of both ligands was not necessary for optimal T cell activation (47) . Because the SVEC4-10 line expresses VCAM-1, there is no reason to assume that ICAM-1 is also needed. Third, some ICAM-1 expression can be induced on the SVEC4-10 line by TNF treatment, but TNF did not render the endothelial line competent at stimulating a proliferative response of A.E7 cells (data not shown).
Despite the lack of costimulatory activity for Thl cell proliferation, SVEC4-10 antigen presentation to A.E7 cells did not induce anergy. The consequences of antigen presentation by viable but costimulator-deficient APCs to Thl cells is largely uncharacterized. Most studies ofclonal anergy, and in particular of anergy induced in the A.E7 clone, have been performed using nonviable, chemically fixed APCs. Although some "nonprofessional" APCs may induce T cell anergy (29, 30) , the consequences of antigen presentation by many other cell types have not been carefully examined. The present results indicate that induction of anergy does not strictly correlate with the lack of costimulators for antigen-induced Thl proliferative responses. Because the molecular events involved in costimulation of IL-2 production (62) and anergy induction (37, 63) are, at best, incompletely defined, there is no a priori reason to assume that the two results ofcostimulatordeficient antigen presentation are necessarily linked. In fact, there is evidence that blockade of the B7-CD28 costimulatory pathway in vivo can inhibit T cell-dependent immune response to protein antigens without induction of tolerance to those antigens (64). The experimental system described here may help to distinguish divergent mechanisms underlying costimulation of IL-2 production versus regulation of anergy induction.
The partial activation response of A.E7 to SVEC4-10 antigen presentation, characterized by induction of IL-2 receptor expression suggests a possible physiological role for endothelial antigen presentation. Antigen-specific interactions of T cells with endothelium in the lumena of microvasculature could upregulate surface molecules required for tight adhesion and extravasation of T cells into tissues without initiating proliferative responses. This would result in selective enrichment of antigen-specific T cells at a site of antigen exposure. Furthermore, upregulation of IL-2R and possibly other molecules by endothelial antigen presentation might result in enhanced functional responses of these T cells to subsequent antigen exposure in extravascular sites. In other words, endothelial cells may direct antigen-specific T cells to sites of extravascular antigen and prepare T cells to respond to tissue-based APCs.
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